Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Uncertainty regarding the effectiveness and safety of intensive low-density lipoprotein cholesterol (LDL-C) reduction in ...

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License ...

Researchers found that gut microbiome composition is strongly linked to metabolic health across different life stages, with ...

FRIDAY, Jan. 24, 2025 (HealthDay News) -- Among older adults and adults with low atherosclerotic cardiovascular disease (ASCVD) risk for whom aspirin is not recommended, use of aspirin decreased after ...

A research team revealed that insulin-like growth factor-binding protein 6 (IGFBP6) serves as a potential therapeutic target ...

Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...

The research team of Professor Sin Gon Kim and Professor Nam Hoon Kim of department of internal medicine (Endocrinology and Metabolism) of Korea University Anam Hospital, and Professor Ji Yoon Kim of ...